Zoltero 4mg Injection

About

Zoltero 4mg Injection contains Zoledronic acid, a potent bisphosphonate that primarily acts as an inhibitor of osteoclastic bone resorption. This medication works by binding to bone mineral and inhibiting the activity of osteoclasts, the cells responsible for breaking down bone tissue. By reducing bone resorption, Zoledronic acid helps to strengthen bones, decrease bone turnover, and prevent skeletal complications associated with various conditions. It is particularly effective in managing hypercalcemia of malignancy, where it rapidly lowers elevated calcium levels, and in preventing skeletal-related events such as pathological fractures and spinal cord compression in patients with bone metastases from solid tumors or multiple myeloma. Its long-lasting effect allows for infrequent dosing, providing significant benefits in bone health management.

Uses

• Hypercalcemia of malignancy
• Bone metastases from solid tumors
• Multiple myeloma with bone lesions
• Paget's disease of bone

Directions For Use

Administered as an intravenous infusion over at least 15 minutes. Ensure adequate hydration before and after administration.

Benefits

• Reduces bone pain and discomfort
• Prevents skeletal-related events (e.g., fractures)
• Lowers high calcium levels in cancer patients
• Improves quality of life for cancer patients
• Long-lasting effect with infrequent dosing
• Strengthens bone structure

Side Effects

• Fever and flu-like symptoms
• Bone, joint, or muscle pain
• Headache
• Nausea and vomiting
• Fatigue
• Anemia
• Hypocalcemia (low calcium levels)
• Kidney impairment (renal dysfunction)
• Osteonecrosis of the jaw (ONJ)
• Atrial fibrillation
• Ocular inflammation
• Injection site reactions

Safety Measures

• Alcohol - No specific interaction with alcohol, but maintaining good hydration is important, especially around infusion times.
• Pregnancy - Contraindicated during pregnancy due to potential for fetal harm. Effective contraception should be used by women of childbearing potential.
• Breastfeeding - Not recommended during breastfeeding, as it is unknown if Zoledronic acid is excreted in human milk.
• Liver - No dose adjustment is typically needed in patients with liver impairment, as Zoledronic acid is not metabolized by the liver.
• Kidney - Contraindicated in patients with severe renal impairment. Dose adjustments are required for moderate renal impairment, and kidney function must be monitored.
• Lung - No specific lung-related safety note, but monitor for fluid overload in patients with pre-existing cardiac or pulmonary conditions due to intravenous administration.

Disclaimer

MedEHub is committed to delivering reliable, expert-reviewd information to help consumers make informed health decisions. However, the content provided on this website is for informational purposes only and is not intended to replace professional medical advice, diagnosis or treatment.

Always consult your doctor for any medical concerns, and discuss your questions about health conditions or medications with a qualified healthcare professional. Do not ignore or delay seeking professional medical advice based on information found on Med E Hub.

Our goal is to complement, not replace, the essential doctor-patient relationship.